N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

Sponsor: Pfizer • ClinicalTrials.gov ID: NCT05611801

Registry updated: 2026-10-14
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called marstacimab) for the potential treatment of hemophilia in pediatric patients. This study will enroll pediatric participants from ages 1 to 17 years in a sequential manner. The study opened the enrollment to adolescent participants aged 12 to 17 years first. Then children aged 6 to 11 years erere permitted to enroll. Lastly, children aged 1 to 5 years are permitted to enroll. This study will enroll male participants who: * have severe Hemophilia A or moderately severe to severe Hemophilia B (with or without inhibitors) * have accurate historical records documenting all factor VIII, factor IX, or bypass agent infusions and hemophilia bleed events for at least 1 year prior to entering the study for participants from 6 to 17 years of age, and at least 3 months prior to entering the study for participants from 1 to 5 years of age * if a non-inhibitor patient, must be on a stable routine prophylaxis regimen with factor VIII or factor IX replacement products for at least 12 months prior to study entry for participants from 6 to 17 years of age, and least 3 months for participants aged from 1 to 5 years of age * if an inhibitor patient, must be on an on-demand bypass treatment regimen during the 12 months prior to study entry for participants from 6 to 17 years of age, and during the 3 months prior to study entry for participants aged from 1 to 5 years of age All participants in this study will receive marstacimab to use prophylactically. Marstacimab will be given once a week as a subcutaneous (under the skin) shot. The first dose of marstacimab will be given at the study site by the study site staff. During the 12-month treatment period, weekly doses of marstacimab can be given at home, or if preferred, the doses may be given by the study site staff. To help us determine if the study medicine is safe and effective, we will compare participant experiences when they are taking the study medicine to a historical period when they were not. Researchers want to see if the study medicine works to prevent the bleeding episodes commonly experienced by patients with Hemophilia. Participants will be in this study for about 14 months (approximately 1 month in a Screening period, 12 months receiving treatment, and 1 month in a follow-up period) during which they will visit the study site at least 10 times. If preferred, and if local regulations allow it, 2 of the study visits can be completed at the participant's home instead of at the study site. There will also be 6 scheduled telephone calls approximately every 2 months.

Interventions

  • marstacimab (Drug)
    marstacimab

Eligibility criteria

Inclusion Criteria: * Male participants of appropriate age and required minimum weight * Participants aged 12 to 17 years must be at least 25 kgs at time of consent. * Participants aged 6 to 11 years must be at least 19 kgs at time of consent. * Participants aged 1 to 5 years must be at least 5 kgs at time of consent. * Participants with a diagnosis of severe hemophilia A or moderately severe to severe hemophilia B * Participants must have at least 1 year (if aged 6 to 17 years), or at least 3 months (if aged 1 to 5 years) of diary and/or medical records available in which exogenous FVIII or FIX replacement or bypass agent infusions and hemophilic bleeding episodes were consistently documented over over the above specified timeframe to the time of consent. Participants who are enrolled into the Non-Inhibitor Cohort must also meet the following criteria: * No current detectable inhibitor and no documented history of inhibitors in the 5 years prior to consent * Must have at least 50 exposure days to FVIII/FIX replacement products for participants aged 6 to 17 years. Participants from 1 to 5 years do not require a minimum documented number of exposure days * Must be at least 80% compliant with a stable and effective routine prophylaxis regimen with FVIII/FIX replacement products, for at least 12 months prior to consent for participants aged 6 to 17 years, for at least 3 months prior to consent for participants from 1 to 5 years Participants who are enrolled into the Inhibitor Cohort must also meet the following criteria: * Documentation of current high titer inhibitor (≥5 BU/mL); or current low titer inhibitor (\<5 BU/mL) refractory to FVIII or FIX replacement and with FVIII or FIX recovery \<60% of expected within previous 12 months prior to the time of consent * Participants who have documented inhibitors while on factor-replacement therapy but who do not meet the high quantitative inhibitor criteria described in the prior bullet at the time of screening (eg, participant with a previously documented high-titer inhibitor ≥5 BU/mL) and whose condition precludes re-challenge with FVIII or FIX replacement may be considered for eligibility on a case-by-case basis with discussion and agreement from the Pfizer medical monitor. * Participants aged 6 to 17 years: Hemophilia A participants with on-demand treatment regimen with ≥12 bleeding episodes or hemophilia B participants with on-demand treatment regimen with ≥8 bleeding episodes (spontaneous or traumatic) necessitating treatment with bypass factor in the 12 months prior to informed consent * Participants aged 1 to 5 years of age with at least 3 months' on-demand bypass treatment regimen and at least 1 treated hemophilic bleeding in the last 3 months or at least 2 treated hemophilic bleedings in the last 6 months documented prior to the time of informed consent * Participants aged 6 to 17 years must be on an on-demand bypass treatment regimen during the 12 months prior to informed consent * Participants aged 1 to 5 years of age must be on an on-demand bypass treatment regimen during the 3 months prior to informed consent Exclusion Criteria: * Known coronary artery, thrombotic, or ischemic disease, or current evidence of congenital or acquired thrombophilic disease such as Anti-thrombin III deficiency, Factor V Leiden mutation, prothrombin 20210 mutation, protein C deficiency, protein S deficiency and antiphospholipid syndrome. * Known planned surgical procedure during the planned study period * Known hemostatic defect other than hemophilia A or B * Abnormal hematology, renal or hepatic function laboratory results at screening * Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, persistent jaundice, or cirrhosis. Participants aged 1 to 5 years with known hepatitis B or C will also be excluded * Known HIV-positive for participants aged 1 to 5 years of age * Other acute or chronic medical or psychiatric condition that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator * Individuals with known allergic reaction or hypersensitivity to hamster protein or other components of the study intervention * Current routine prophylaxis with bypassing agent, non-coagulation non-factor replacement therapy (eg, emicizumab), or any previous treatment with a gene therapy product for treatment of hemophilia * Participants with inhibitors who are being treated using a prophylaxis treatment regimen with a bypass agent, and, participants who have previously received non-factor-based hemophilia therapy (eg, fitusiran, concizumab, emicizumab) will be considered on a case-by-case basis, only after discussion and agreement between the investigator and the Pfizer medical monitor * Regular use of immunomodulatory medications (eg, IVIG, routine systemic corticosteroids, rituximab) * Use of systemic antifibrinolytics, medications that may increase the risk of bleeding, and certain non-steroidal anti-inflammatory drugs within 120 hours of first dose of study intervention and while on study. Some of these agents may be permitted if it is authorized for use in the respective country, is part of the standard of care in the study population, its use is short term and on a PRN basis and following discussion with the Pfizer medical monitor. * Ongoing or planned use of ITI, or prophylaxis with FVIII or FIX replacement at any time after initiation of treatment with study intervention * Participation in other studies involving investigational drug(s) or investigational vaccine(s) within 30 days (or as determined by local requirements) or 5 half-lives prior to study entry or during study participation * Previous exposure to marstacimab during participation in other marstacimab clinical studies * CD4 cell count ≤200/uL if HIV-positive, for participants aged 6 to 17 years * Abnormal ECG of clinical relevance that may affect participant safety or interpretation of study results * Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members

Conditions

Hemophilia A Hemophilia B

Locations

  • Intermountain - Primary Children's Hospital — Salt Lake City, Utah, United States
  • Arbesu Hematología — Mendoza, Mendoza Province, Argentina
  • Murdoch Children's Research Institute — Parkville, Australia
  • Medizinische Universität Wien — Vienna, State of Vienna, Austria
  • Centro Estadual de Hemoterapia e Hematologia Marcos Daniel Santos - HEMOES — Maruípe, VITÓRIA, Brazil
  • Stollery Children's Hospital — Edmonton, Alberta, Canada
  • Hamilton Health Sciences - McMaster University/McMaster Children's Hospital — Hamilton, Ontario, Canada
  • Beijing Children's hospital, Capital Medical University — Beijing, Beijing Municipality, China
  • Southern Medical University Nanfang Hospital — Guangzhou, Guangdong, China
  • The Affiliated Hospital of Guizhou Medical University — Guiyang, Guizhou, China
  • Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology — Wuhan, Hubei, China
  • Tongji Hospital of Tongji Medical College of HUST/Pediatric Hematology Department Pharmacy — Wuhan, Hubei, China
  • Jiangxi Provincial People's Hospital — Nanchang, Jiangxi, China
  • Institute of hematology&blood disease hospital — Tianjin, Tianjin Municipality, China
  • Detska nemocnice FN Brno — Brno, Brno-město, Czechia
  • Fakultni nemocnice Brno — Brno, Czechia
  • Fakultni Nemocnice Motol a Homolka — Prague, Czechia
  • Aarhus University — Aarhus N, Aarhus N, Denmark
  • Rigshospitalet — Copenhagen, Capital Region, Denmark
  • Aarhus Universitetshospital, Skejby — Aarhus N, Denmark
  • Charité Campus Virchow-Klinikum — Berlin, State of Berlin, Germany
  • Nirmal Hospital Pvt Ltd. — Surat, Gujarat, India
  • K. J. Somaiya Hospital and Research Centre, Somaiya Ayurvihar Complex — Mumbai, Maharashtra, India
  • Nil Ratan Sircar Medical College and Hospital — Kolkata, West Bengal, India
  • Sheba Medical Center — Ramat Gan, Central District, Israel
  • IRCCS Istituto Giannina Gaslini — Genoa, Liguria, Italy
  • Istituto Clinico Humanitas - Humanitas Mirasole SPA — Rozzano, Milan, Italy
  • Azienda Ospedaliero Universitaria di Parma — Parma, PARMA, Italy
  • Ospedale Pediatrico Bambino Gesù IRCCS — Rome, ROMA, Italy
  • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino — Torino, TORINO, Italy
  • Hyogo prefectural Kobe Children's Hospital — Kobe, Hyōgo, Japan
  • Nagano Children's Hospital — Azumino, Nagano, Japan
  • Nara Medical University Hospital — Kashihara, Nara, Japan
  • Saga University Hospital — Saga, Saga-ken, Japan
  • Saitama Prefectural Children's Medical Center — Saitama-shi, Saitama, Japan
  • Arké SMO S.A de C.V — Veracruz, Veracruz, Mexico
  • King Fahad Specialist Hospital — Dammam, Dammam, Saudi Arabia
  • Detska fakultna nemocnica Kosice — Košice, Slovakia
  • Univerzitna nemocnica Martin — Martin, Slovakia
  • Worthwhile Clinical Trials — Benoni, Gauteng, South Africa
  • Charlotte Maxeke Johannesburg Academic Hospital — Johannesburg, Gauteng, South Africa
  • Severance Hospital, Yonsei University Health System — Seoul, Seoul-teukbyeolsi [seoul], South Korea
  • Kyung Hee University Hospital at Gangdong — Seoul, Seoul-teukbyeolsi [seoul], South Korea
  • Kyungpook National University Hospital — Daegu, Taegu-kwangyǒkshi, South Korea
  • Hospital Universitario La Paz — Madrid, Madrid, Comunidad de, Spain
  • Hospital Universitario Miguel Servet — Zaragoza, ZARAGOZA, Spain
  • Taichung Veterans General Hospital — Taichung, Taiwan
  • National Taiwan University Hospital — Taipei, Taiwan
  • Adana Acibadem Hastanesi Pediatrik Hematoloji Bilim Dali — Adana, Adana, Turkey (Türkiye)
  • Gazi University Medical Faculty — Ankara, Ankara, Turkey (Türkiye)
  • Gazi Universitesi Tip Fakultesi Hastanesi Cocuk Hematologi Bolumu — Ankara, Ankara, Turkey (Türkiye)
  • Istanbul Universitesi Istanbul Tıp Fakultesi Hastanesi — Istanbul, Istanbul, Turkey (Türkiye)
  • Ege Universitesi Tip Fakultesi Hastanes — Izmir, İzmir, Turkey (Türkiye)
  • Erciyes University Faculty of Medicine Pediatric — Kayseri, Kayseri, Turkey (Türkiye)
  • Erciyes University Health Application and Research Center Directorate — Melikgazi, Kayseri, Turkey (Türkiye)
  • Ondokuz Mayıs Universitesi — Samsun, Samsun, Turkey (Türkiye)
  • Gazi University Health Research and Application Center Gazi Hospital — Ankara, Turkey (Türkiye)
  • Ege University — Izmir, Turkey (Türkiye)
  • Royal Victoria Infirmary — Newcastle upon Tyne, England, United Kingdom
  • Birmingham Children's Hospital — Birmingham, United Kingdom
  • Evelina London Children's Hospital — London, United Kingdom
  • Royal Manchester Children's Hospital — Manchester, United Kingdom
  • Freeman Hospital — Newcastle upon Tyne, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record